FDA's Office Of Orphan Products Development Grants Rare Pediatric Disease Drug Designation To NanoViricides' Antiviral Drug NV-387
NanoViricides, Inc., a publicly traded company (NYSE American: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that its clinical stage, broad-spectrum, antiviral